These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 39121538)

  • 1. Tyrosine and tryptophan in urine as biomarkers for prostate cancer: A validation study.
    Nasimi H; Madsen JS; Zedan AH; Schmedes AV; Malmendal A; Osther PJS; Alatraktchi FA
    J Pharm Biomed Anal; 2024 Nov; 250():116398. PubMed ID: 39121538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between stage of prostate cancer and tyrosine and tryptophan in urine samples measured electrochemically.
    Nasimi H; Madsen JS; Zedan AH; Schmedes AV; Malmendal A; Osther PJS; Alatraktchi FA
    Anal Biochem; 2022 Jul; 649():114698. PubMed ID: 35523287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer.
    Li C; Zang T; Wrobel K; Huang JT; Nabi G
    Anal Bioanal Chem; 2015 May; 407(12):3393-404. PubMed ID: 25724369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
    Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
    PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel candidate urinary protein biomarkers for prostate cancer in a multiethnic cohort of South African patients via label-free mass spectrometry.
    Adeola HA; Soares NC; Paccez JD; Kaestner L; Blackburn JM; Zerbini LF
    Proteomics Clin Appl; 2015 Jun; 9(5-6):597-609. PubMed ID: 25708745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
    Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
    Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Furan and p-xylene as candidate biomarkers for prostate cancer.
    Jiménez-Pacheco A; Salinero-Bachiller M; Iribar MC; López-Luque A; Miján-Ortiz JL; Peinado JM
    Urol Oncol; 2018 May; 36(5):243.e21-243.e27. PubMed ID: 29395956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting tryptophan and tyrosine metabolism by liquid chromatography tandem mass spectrometry.
    Marcos J; Renau N; Valverde O; Aznar-Laín G; Gracia-Rubio I; Gonzalez-Sepulveda M; Pérez-Jurado LA; Ventura R; Segura J; Pozo OJ
    J Chromatogr A; 2016 Feb; 1434():91-101. PubMed ID: 26818237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer.
    Jedinak A; Curatolo A; Zurakowski D; Dillon S; Bhasin MK; Libermann TA; Roy R; Sachdev M; Loughlin KR; Moses MA
    BMC Cancer; 2015 Apr; 15():259. PubMed ID: 25884438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
    Yu C; Niu L; Li L; Li T; Duan L; He Z; Zhao Y; Zou L; Wu X; Luo C
    Prostate; 2021 Dec; 81(16):1320-1328. PubMed ID: 34590739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of amino acids in urine of patients with prostate cancer and benign prostate growth.
    Sroka WD; Boughton BA; Reddy P; Roessner U; Słupski P; Jarzemski P; Dąbrowska A; Markuszewski MJ; Marszałł MP
    Eur J Cancer Prev; 2017 Mar; 26(2):131-134. PubMed ID: 27222937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening, identification of prostate cancer urinary biomarkers and verification of important spots.
    Zhao H; Zhao X; Lei T; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):935-947. PubMed ID: 30610587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of miRNAs in urine of prostate cancer patients.
    Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
    Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.
    Rehman I; Azzouzi AR; Catto JW; Allen S; Cross SS; Feeley K; Meuth M; Hamdy FC
    Urology; 2004 Dec; 64(6):1238-43. PubMed ID: 15596215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel biomarkers for risk of prostate cancer: results from a case-control study.
    Yang L; Gaikwad NW; Meza J; Cavalieri EL; Muti P; Trock B; Rogan EG
    Prostate; 2009 Jan; 69(1):41-8. PubMed ID: 18816637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.
    Yan C; Kim YH; Kang HW; Seo SP; Jeong P; Lee IS; Kim D; Kim JM; Choi YH; Moon SK; Yun SJ; Kim WJ
    J Korean Med Sci; 2015 Dec; 30(12):1784-92. PubMed ID: 26713053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers.
    Mengual L; Lozano JJ; Ingelmo-Torres M; Izquierdo L; Musquera M; Ribal MJ; Alcaraz A
    BMC Cancer; 2016 Feb; 16():76. PubMed ID: 26856686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic Identification of Small Extracellular Vesicle Proteins LAMB1 and Histone H4 for Prostate Cancer Diagnosis and Risk Stratification.
    Pang B; Wang Q; Chen H; Liu Z; Han M; Gong J; Yue L; Ding X; Wang S; Yan Z; Chen Y; Malouf D; Bucci J; Guo T; Zhou C; Jiang J; Li Y
    Adv Sci (Weinh); 2024 Jun; 11(23):e2402509. PubMed ID: 38590132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer antigen 3 gene expression in peripheral blood and urine sediments from prostate cancer and benign prostatic hyperplasia patients versus healthy individuals.
    Moradi Sardareh H; Goodarzi MT; Yadegar-Azari R; Poorolajal J; Mousavi-Bahar SH; Saidijam M
    Urol J; 2014 Nov; 11(6):1952-8. PubMed ID: 25433473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
    Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
    J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.